Supply Chain

Dual chokepoint disruptions in the Gulf and Red Sea are pushing shippers toward longer, costlier routes with no resolution in sight.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Serialization data does more than meet DSCSA rules. See how connected event histories improve recalls, returns and inventory visibility.

Nick Niemeyer of API Innovation Center on how the National Fragility Index could help reduce US drug shortage risk.

The Section 232 tariff deadline for 17 major drugmakers has arrived. Here's what pharma supply chain teams need to know now.

Domestic manufacturing can reduce certain dependencies, but reliable pharmaceutical commercialization requires qualified redundancy, sustainable economics, quality maturity and decision-ready visibility across the full supply network.

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Peli BioThermal and PAXAFE are partnering to pair cold chain packaging with AI-powered monitoring, signaling where pharma logistics technology is headed next.

Shortages of antibiotics, IV fluids and sterile injectables are hardening as new EU and US rules push pharma to fix the incentives behind them.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

How commercial trade groups are shifting from distribution execution to strategic partners shaping market access, launch readiness and commercial performance.

The models pharma inherited were built for conditions that have changed. A look across the August issue at an industry redesigning itself.

Continuous monitoring, targeted automation and interoperability standards are redefining pharma cold chain custody and cutting temperature excursions.

EVERSANA's Danny Williams on how cell and gene therapies, AI, and direct-to-patient fulfillment are reshaping the pharma 3PL model.

The API Innovation Center's Gerren McHam on China's new supply chain rules, reshoring policy, and where US drug manufacturing goes next.

Specialty drugs, cell and gene therapies, and GLP-1s are reshaping pharma distribution, forcing 3PLs to build for both precision and scale.

ORBIS' Matt Marchetti outlines how pharma companies can define supply chain impact, KPIs, and ROI when transitioning to reusable plastic pallets.

As China tightens supply chain rules, tariff pressure persists, and the FDA's PreCheck Program takes shape, this FAQ breaks down how pharma reshoring stands in 2026.

The FDA selected seven companies, including two CGT manufacturers, for its PreCheck Pilot to accelerate domestic manufacturing approvals and bolster supply chain resilience.

As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

The investment adds 27 temperature-controlled freight facilities across the Americas, Europe, and Asia as demand for biologics distribution infrastructure continues to climb.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.